Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07129642) titled 'Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease' on Aug. 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Zhongshan Hospital
Condition:
Graves Disease
Intervention:
Biological: Allogeneic CAR-T
Recruitment Status: Recruiting
Phase: Early Phase 1
Date of First Enrollment: August 10, 2025
Target Sample Size: 5
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07129642
Published by HT Digital Content Services with pe...